An ageing population in Asia has expanded the scope for pharmaceutical companies. And countries, in turn, are using regulation to speed up the drug development process as they embrace a dynamic life science market.
This demographic shift has attracted the attention of investors outside the region. In an exclusive interview with FinanceAsia, Nicholas Galakatos, head of the Blackstone Life Sciences business, shares his views on the development of the life science sector in Asia.
Galakatos joined Blackstone as part of its acquisition of Clarus in December last year, indeed he had co-founded Clarus in 2005. Galakatos has more than 30 years of industry...
¬ Haymarket Media Limited. All rights reserved.
